Things don’t always go quite according to plan in the biotech world – something both Seattle Genetics and Cascadian Therapeutics know only too well.
Seattle Genetics was thwarted in its attempted $2 billion licensing deal with Immunomedics, for its lead solid-tumour drug, by activist investors that weren’t prepared to accept the deal offered by the former company.
